Viewing nowTopiramate 25 mg Tablets
Topiramate 25mg
Tablet · Prescription medication
Daihan New Pharm Co., Ltd.

MFDS item code 200704968 · Notified 2007.04.30
Treatment of epilepsy (partial seizures, generalized seizures, etc.); prevention of migraine
This medication is effective for treating epilepsy, and is used as monotherapy for partial seizures with or without secondary generalized seizures in children over 6 years old and adults. It is also used as an adjunct therapy for patients over 2 years old who have difficulty controlling seizures with existing treatment, improving secondary generalized seizures, seizures associated with Lennox-Gastaut syndrome, and primary generalized tonic-clonic seizures. Additionally, it helps in the prevention of migraines. Therefore, it is widely used for the management of epilepsy and migraines.
It is preferable to start this medicine at a low dose and increase it to the effective dose. There is no need to monitor blood concentrations to optimize administration of this medicine. The recommended dose of this medicine is the same for all adults and children, including the elderly, in the absence of renal disease. This medicine may be taken with or without food. The tablet should be swallowed whole and not crushed. Epilepsy monotherapy, adults (17 years and older): Initiate treatment with 25㎎ in the evening for the first week. Thereafter, increase the dose by 25 or 50㎎ daily at intervals of 1-2 weeks and administer in 2 divided doses daily. If the patient has difficulty tolerating this titration schedule, extend the titration intervals. The dose and rate of titration should be determined according to clinical response. The recommended dose for monotherapy in adults is 100~200mg daily. The maximum recommended dose is 500㎎ daily. Some patients with recurrent epilepsy have tolerated doses of up to 1,000㎎ daily during topiramate monotherapy. Epilepsy adjunctive therapy, adults (17 years and older): The minimum effective dose is 200mg daily, and the usual dose is 200-400mg daily in 2 divided doses. Depending on the patient, the dose may be increased to the maximum recommended dose of 800mg daily. Initiate treatment with 25-50mg in the evening for the first week; starting at a lower dose is also possible. Thereafter, increase the dose by 25-50mg at intervals of 1-2 weeks and administer in 2 divided doses daily. If the patient has difficulty tolerating the increased dose, the dose increments may be reduced or the titration intervals extended. The dose should be determined according to clinical effect. Migraine prophylaxis, adults: Initiate treatment with 25mg of this medicine in the evening for the first week. Thereafter, increase the dose by 25mg/day at weekly intervals. If the patient has difficulty tolerating this titration, extend the titration intervals. The recommended dose is 100mg daily, administered in 2 divided doses. Some patients may respond to a dose of 50mg daily. Doses of up to 200mg daily may be administered; the dose and rate of titration should be determined according to clinical response. For patients with moderate or severe renal impairment (CLcr < 70 mL/min/1.73 m2), it is recommended that the initial and maintenance doses be reduced to approximately 1/2. Patients on hemodialysis: Because this medicine is removed from plasma by hemodialysis, increase the dose of this medicine by approximately 1/2 on dialysis days. Increase the dose taking into account the duration of dialysis, dialyzer clearance, and the patient's residual renal clearance, and administer the dose in divided amounts at the beginning and end of hemodialysis. Use with caution in patients with hepatic impairment, as clearance of this medicine may be reduced.
Epilepsy monotherapy, children (6-16 years): Initiate treatment with 0.5-1㎎/㎏ in the evening for the first week. Thereafter, increase the dose by 0.5-1㎎/㎏ daily at intervals of 1-2 weeks and administer in 2 doses daily. If the patient has difficulty tolerating the dose increase, reduce the dose increments or extend the titration intervals. The dose and degree of titration should be determined according to clinical response. The recommended dose for monotherapy in children is 3-6mg/kg daily. Doses of up to 500㎎ daily have been used in children diagnosed with partial seizures. Epilepsy adjunctive therapy, children (2-16 years): The recommended dose is approximately 5-9mg/kg daily, administered in 2 divided doses. Administer 25mg (or less, based on 1-3mg/kg daily) in the evening for the first week, and thereafter increase the dose by 1-3mg/kg daily at intervals of 1-2 weeks, in 2 divided doses, until an appropriate clinical effect is achieved. Dose titration should be determined according to clinical effect. Doses of up to 30mg/kg daily have been administered, and were generally well tolerated.
This medication is used for the treatment of epilepsy and the prevention of migraines. Patients taking this medication may have an increased risk of suicidal thoughts or behaviors, so both patients and caregivers should inform healthcare providers immediately if there are mood changes or abnormal behaviors. Moreover, this medication can cause serious skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis, so if there are any abnormal skin symptoms, the medication should be stopped immediately and medical attention sought. This medication may cause harm to the fetus if used during pregnancy, so women who might become pregnant should perform a pregnancy test before taking it and must use effective birth control during treatment. For patients with poor kidney function or those undergoing dialysis, dose adjustments of this medication are necessary, and adequate hydration is important due to the risk of kidney stones. This medication can affect the central nervous system, causing drowsiness, dizziness, blurred vision, etc. Therefore, it's advisable to avoid driving or operating machinery during initial use. Suddenly stopping the medication can lead to seizures, so dosage should be tapered gradually according to a doctor's instructions. This medication may interact with other antiseizure medications or various drugs, so if any medications are being taken, it is essential to inform healthcare providers, particularly since the effectiveness of birth control may be reduced when taken with contraceptives. During treatment, various side effects may occur, including weight loss, appetite decrease, depression, memory impairment, nausea, diarrhea, etc. If any abnormal symptoms persist or worsen, consult with a healthcare provider. Regular tests to monitor blood status, kidney function, liver function, and intraocular pressure are recommended while taking this medication. Finally, this medication contains lactose, so patients with lactose intolerance should not take it.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius.
White round film-coated tablets
30 tablets/bottle, 100 tablets/bottle, 500 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTopiramate 25mg
Tablet · Prescription medication
Daihan New Pharm Co., Ltd.

Topiramate 100mg
Tablet · Prescription medication
Ildong Pharmaceutical Co., Ltd.

Topiramate 100mg
Tablet · Prescription medication
Myungin Pharmaceutical Co., Ltd.

Topiramate 100mg
Tablet · Prescription medication
Albozencore Co., Ltd.

Topiramate 100mg
Tablet · Prescription medication
Pamgen Science Co., Ltd.

Topiramate 25mg
Tablet · Prescription medication
Myungjin Pharmaceutical Co., Ltd.

Topiramate 100mg
Tablet · Prescription medication
Hanlin Pharmaceutical Co., Ltd.

Topiramate 100mg
Tablet · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.